Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Analyses of the FranceCoag cohort support differences in immunogenicity among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A.

Calvez T, Chambost H, d'Oiron R, Dalibard V, Demiguel V, Doncarli A, Gruel Y, Huguenin Y, Lutz P, Rothschild C, Vinciguerra C, Goudemand J; for FranceCoag Collaborators.

Haematologica. 2018 Jan;103(1):179-189. doi: 10.3324/haematol.2017.174706. Epub 2017 Oct 12.

2.

Use of clinical practice guidelines on long-term prophylaxis in severe hemophilia in France: a retrospective audit.

Meunier S, Chambost H, Demiguel V, Doncarli A, Suzan F, Trossaƫrt M.

J Pediatr. 2013 Jun;162(6):1241-4, 1244.e1. doi: 10.1016/j.jpeds.2012.11.080. Epub 2013 Jan 17.

PMID:
23333129
3.

Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A.

Goudemand J, Rothschild C, Demiguel V, Vinciguerrat C, Lambert T, Chambost H, Borel-Derlon A, Claeyssens S, Laurian Y, Calvez T; FVIII-LFB and Recombinant FVIII study groups.

Blood. 2006 Jan 1;107(1):46-51. Epub 2005 Sep 15.

4.

Intracranial haemorrhages in French haemophilia patients (1991-2001): clinical presentation, management and prognosis factors for death.

Stieltjes N, Calvez T, Demiguel V, Torchet MF, Briquel ME, Fressinaud E, Claeyssens S, Coatmelec B, Chambost H; French ICH Study Group.

Haemophilia. 2005 Sep;11(5):452-8.

PMID:
16128887
5.

[Factors associated with refusal of organ donation in France from 1996 to 1999].

Demiguel V, Boileau C, Cohen S, Noury D, Bonnet F, Tuppin P.

Ann Fr Anesth Reanim. 2001 Dec;20(10):826-32. French.

PMID:
11803842

Supplemental Content

Loading ...
Support Center